IP Library › Granted Patent US 12,237,084
Granted Patent B2
US 12,237,084 · App. 17/226,021 · Granted Feb 25, 2025

System for assessing and mitigating potential spread of infectious disease among dialysis patients

Inventors: Caitlin Kelly Monaghan (Arlington, MA); Peter Kotanko (New York, NY); John Larkin (Hudson, MA); Jeffrey Hymes (Nashville, TN); Kathleen Belmonte (Concord, MA); Len Usvyat (Boston, MA); Ines A. Dahne-Steuber (Marietta, GA); Franklin W. Maddux (Lincoln, MA)
Assignee: Fresenius Medical Care Holdings, Inc.
G16H50/30G16H20/00G16H20/40G16H50/20G16H50/70G16H50/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,237,084
App. No.
17/226,021
Granted
Feb 25, 2025
Kind
B2
Abstract

A method for mitigating the spread of infectious diseases among dialysis patients is provided. The method comprises: receiving, by a prediction system and from a medical facility, individual treatment data indicating dialysis treatment information associated with a patient undergoing dialysis treatment; receiving, by the prediction system and from a blood testing laboratory, individual lab data indicating blood analysis information associated with the patient; determining, by the prediction system, disease analysis results for the patient based on inputting the individual treatment data and the individual lab data into a disease prediction machine learning (ML) model, wherein the disease analysis results indicate a likelihood of the patient being infected with a contagious disease; and providing, by the prediction system and to the medical facility, instructions indicating one or more responsive actions based on the disease analysis results.

Claims (67)

1. A method, comprising:

training, by a prediction system, a first disease prediction machine learning (ML) model based on geographical disease data indicating new reported cases of a contagious disease within a first geographical area;

receiving, by the prediction system and from a medical facility, individual treatment data indicating dialysis treatment information associated with a patient undergoing an initial dialysis treatment, wherein the medical facility is associated with the first geographical area;

receiving, by the prediction system and from a blood testing laboratory, individual lab data indicating blood analysis information associated with the patient;

determining, by the prediction system, disease analysis results for the patient based on inputting the individual treatment data and the individual lab data into the first disease prediction ML model, wherein the disease analysis results indicate a likelihood of the patient being infected with the contagious disease;

providing, by the prediction system and to the medical facility, instructions indicating one or more responsive actions based on the disease analysis results, wherein the one or more responsive actions comprise lowering an ultrafiltration rate for the patient to use for a subsequent dialysis treatment;

performing, by a dialysis machine located at the medical facility, the subsequent dialysis treatment for the patient using the lowered ultrafiltration rate;

receiving, by the prediction system and from the medical facility, feedback information indicating a plurality of inaccuracy counts associated with the disease analysis results; and

based on comparing the plurality of inaccuracy counts with one or more thresholds, re-training, by the prediction system, the first disease prediction ML model.

2. The method of claim 1 , further comprising:

receiving, by the prediction system, group treatment data indicating dialysis treatment information associated with a plurality of patients undergoing the initial dialysis treatment; and

receiving, by the prediction system, group lab data indicating blood analysis information associated with the plurality of patients undergoing the initial dialysis treatment,

wherein training the first disease prediction ML model is further based on the group treatment data and the group lab data.

3. The method of claim 2 , further comprising:

receiving, by the prediction system, group physician data indicating clinical or treatment notes associated with the plurality of patients undergoing the initial dialysis treatment,

wherein training the first disease prediction ML model is further based on the group physician data.

4. The method of claim 3 , further comprising:

receiving, by the prediction system and from the medical facility, individual physician data indicating clinical or treatment notes associated with the patient undergoing the initial dialysis treatment, and

wherein determining the disease analysis results is further based on inputting the individual physician data into the first disease prediction ML model.

5. The method of claim 2 , further comprising:

obtaining, by the prediction system, group patient data indicating patient demographics and history associated with the plurality of patients undergoing the initial dialysis treatment,

wherein training the first disease prediction ML model is further based on the group patient data.

6. The method of claim 5 , further comprising:

receiving, by the prediction system, individual patient data indicating clinical or treatment notes associated with the patient undergoing the initial dialysis treatment, and

wherein determining the disease analysis results is further based on inputting the individual patient data into the first disease prediction ML model.

7. The method of claim 2 , wherein the group treatment data is associated with the medical facility and the geographical disease data further indicates new reported cases of the contagious disease within a second geographical area, and wherein the method further comprises:

training, by the prediction system and based on the geographical disease data, a second disease prediction ML model for a second medical facility that is within the second geographical area;

determining that the individual treatment data is from the medical facility that is associated with the first geographical area; and

selecting to use the first disease prediction ML model for the patient rather than the second disease prediction ML model based on determining that the individual treatment data is from the medical facility that is associated with the first geographical area.

8. The method of claim 7 , wherein the first disease prediction ML model is a first eXtreme Gradient Boosting (XGBoost) model comprising a plurality of first decision trees and the second disease prediction ML model is a second XGBoost model comprising a plurality of second decision trees that are different from the plurality of first decision trees.

9. The method of claim 8 , wherein training the first disease prediction ML model comprises generating the plurality of first decision trees, wherein training the second disease prediction ML model comprises generating the plurality of second decision trees, and wherein a set of decision trees from the plurality of second decision trees are different from decision trees within the plurality of first decision trees based on the geographical disease data indicating different newly reported cases of the contagious disease within the first geographical area and the second geographical area.

10. The method of claim 1 , wherein the first disease prediction ML model is a deep learning model.

11. The method of claim 1 , wherein the one or more responsive actions further comprise initiating a treatment regimen for the patient, allocating personal protective equipment (PPE) for the medical facility, or adjusting patient scheduling to re-assign the patient to an isolation shift for the subsequent dialysis treatment.

12. A prediction system, comprising:

one or more processors; and

a non-transitory computer-readable medium having processor-executable instructions stored thereon, wherein the processor-executable instructions, when executed by the one or more processors, facilitate:

training a first disease prediction machine learning (ML) model based on geographical disease data indicating new reported cases of a contagious disease within a first geographical area;

receiving, from a medical facility, individual treatment data indicating dialysis treatment information associated with a patient undergoing initial dialysis treatment, wherein the medical facility is associated with the first geographical area;

receiving, from a blood testing laboratory, individual lab data indicating blood analysis information associated with the patient;

determining disease analysis results for the patient based on inputting the individual treatment data and the individual lab data into the first disease prediction ML model, wherein the disease analysis results indicate a likelihood of the patient being infected with the contagious disease;

providing, to the medical facility, instructions indicating one or more responsive actions based on the disease analysis results, wherein the one or more responsive actions comprise lowering an ultrafiltration rate for the patient to use for a subsequent dialysis treatment, wherein a dialysis machine located at the medical facility performs the subsequent dialysis treatment for the patient using the lowered ultrafiltration rate;

receiving, from the medical facility, feedback information indicating a plurality of inaccuracy counts associated with the disease analysis results; and

based on comparing the plurality of inaccuracy counts with one or more thresholds, re-training the first disease prediction ML model.

13. The prediction system of claim 12 , wherein the processor-executable instructions, when executed by the one or more processors, further facilitate:

receiving group treatment data indicating dialysis treatment information associated with a plurality of patients undergoing the initial dialysis treatment; and

receiving group lab data indicating blood analysis information associated with the plurality of patients undergoing the initial dialysis treatment,

wherein training the first disease prediction ML model is further based on the group treatment data and the group lab data.

14. The prediction system of claim 13 , wherein the processor-executable instructions, when executed by the one or more processors, further facilitate:

receiving group physician data indicating clinical or treatment notes associated with the plurality of patients undergoing the initial dialysis treatment,

wherein training the first disease prediction ML model is further based on the group physician data.

15. The prediction system of claim 14 , wherein the processor-executable instructions, when executed by the one or more processors, further facilitate:

receiving, from the medical facility, individual physician data indicating clinical or treatment notes associated with the patient undergoing the initial dialysis treatment, and

wherein determining the disease analysis results is further based on inputting the individual physician data into the first disease prediction ML model.

16. The prediction system of claim 13 , wherein the processor-executable instructions, when executed by the one or more processors, further facilitate:

obtaining group patient data indicating patient demographics and history associated with the plurality of patients undergoing the initial dialysis treatment,

wherein training the first disease prediction ML model is further based on the group patient data.

17. The prediction system of claim 16 , wherein the processor-executable instructions, when executed by the one or more processors, further facilitate:

receiving individual patient data indicating clinical or treatment notes associated with the patient undergoing the initial dialysis treatment, and

wherein determining the disease analysis results is further based on inputting the individual patient data into the first disease prediction ML model.

18. A non-transitory computer-readable medium having processor-executable instructions stored thereon, wherein the processor-executable instructions, when executed, facilitate:

training a first disease prediction machine learning (ML) model based on geographical disease data indicating new reported cases of a contagious disease within a first geographical area;

receiving, from a medical facility, individual treatment data indicating dialysis treatment information associated with a patient undergoing initial dialysis treatment, wherein the medical facility is associated with the first geographical area;

receiving, from a blood testing laboratory, individual lab data indicating blood analysis information associated with the patient;

determining disease analysis results for the patient based on inputting the individual treatment data and the individual lab data into the first disease prediction ML model, wherein the disease analysis results indicate a likelihood of the patient being infected with the contagious disease;

providing, to the medical facility, instructions indicating one or more responsive actions based on the disease analysis results, wherein the one or more responsive actions comprise lowering an ultrafiltration rate for the patient to use for a subsequent dialysis treatment, wherein a dialysis machine located at the medical facility performs the subsequent dialysis treatment for the patient using the lowered ultrafiltration rate;

receiving, from the medical facility, feedback information indicating a plurality of inaccuracy counts associated with the disease analysis results; and

based on comparing the plurality of inaccuracy counts with one or more thresholds, re-training, by the prediction system, the first disease prediction ML model.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2021
From: MONAGHAN, CAITLIN KELLY; KOTANKO, PETER; LARKIN, JOHN; HYMES, JEFFREY; BELMONTE, KATHLEEN; USVYAT, LEN; DAHNE-STEUBER, INES A.; MADDUX, FRANKLIN W.
To: FRESENIUS MEDICAL CARE HOLDINGS, INC.
Reel/Frame 056038/0865 →
Continuity (2)
Provisional Application 63008626 · Apr 10, 2020
Related Publication 20210319905A1 · Oct 14, 2021
References Cited (68)
US 9801993B2 · Barrett et al. · 2017 [cited by applicant]
US 20090112102A1 · Roeher · 2009 [cited by examiner]
US 20130191158A1 · Fillmore · 2013 [cited by examiner]
US 20140167917A2 · Wallace · 2014 [cited by examiner]
US 20150149096A1 · Soykan · 2015 [cited by examiner]
US 20150213224A1 · Amarasingham · 2015 [cited by examiner]
US 20190057774A1 · Velez · 2019 [cited by examiner]
US 20200005947A1 · Blanchard et al. · 2020 [cited by applicant]
US 20200065679A1 · Javeri · 2020 [cited by examiner]
US 20200113505A1 · Clingman · 2020 [cited by examiner]
US 20200176112A1 · Sati · 2020 [cited by examiner]
CN 109656918A · 2019 [cited by examiner]
JP 6418624B2 · 2018 [cited by examiner]
WO WO2006113987A1 · 2006 [cited by examiner]
L. Torlay et al., Machine learning-XGBoost analysis of language networks to classify patients with epilepsy, Apr. 22, 2017, Brain Informatics vol. 4, pp. 159-169 (Year: 2017). [cited by examiner]
Ping-Nam Wong, Siu-Ka Mak, Kin-Yee Lo, Gensy M.W Tong, Yuk Wong, Chi-Leung Watt, Andrew K.M Wong, Clinical presentation and outcome of severe acute respiratory syndrome in dialysis patients, American Journal of Kidney D… [cited by examiner]
R. Saran et al. Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS, Kidney International, vol. 69, Issue 7, 2006 (Year: 2006). [cited by examiner]
Saran et al., Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS, Kidney International, vol. 69, Issue 7, 2006, pp. 1222-1228 (Year: 2006). [cited by examiner]
International Patent Application No. PCT/US2021/026455, International Search Report (Jul. 26, 2021). [cited by applicant]
Adams et al. “Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States” [cited by applicant]
Ahamad et al., “A Machine Learning Model to Identify Early Stage Symptoms of SARS-Cov-2 Infected Patients,” [cited by applicant]
Alimadadi et al., “Artificial Intelligence and Machine Learning to Fight COVID-19,” [cited by applicant]
Anand et al., “Prevalence of SARS-CoV-2 Antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study,” [cited by applicant]
Banerjee et al., “Use of Machine Learning and Artificial Intelligence to predict SARS-CoV-2 infection from Full Blood Counts in a population,” [cited by applicant]
Basile et al., “Recommendations for the Prevention, Mitigation and Containment of the Emerging SARS-CoV-2 (COVID-19) Pandemic in Haemodialysis Centres,” [cited by applicant]
Bogoch et al., “Pneumonia of Unknown Aetiology in Wuhan, China: Potential for International Spread via Commercial Air Travel,” [cited by applicant]
CDC COVID-19 Response Team, “Geographic Differences in COVID-19 Cases, Deaths, and Incidence—United States,” MMWR Morb. Mortal Wkly. Rep., vol. 69(15), 465-471 (Apr. 17, 2020). [cited by applicant]
Chen et al., “XGBoost: A Scalable Tree Boosting System,” [cited by applicant]
Cheng et al., “Kidney Disease is Associated with In-Hospital Death of Patients With COVID-19,” [cited by applicant]
COVID-19 Resource and Education Center, Fresenius Medical Care North America, https://lmcna.com/covid-19-resource-center/ (Apr. 15, 2021). [cited by applicant]
Du et al., “Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study,” [cited by applicant]
ERACODA—“The Era-Edta COVID-19 Database for Patients on Kidney Replacement Therapy,” ERAEDTA, https://www.era-edta.org/en/wpcontent/uploads/2020/04/ERACODA-Study-Report-2020-04-29.pdf (Apr. 29, 2020). [cited by applicant]
Feng et al., “A Novel Artificial Intelligence-Assisted Triage Tool to Aid in the Diagnosis of Suspected COVID-19 Pneumonia Cases in Fever Clinics,” [cited by applicant]
Fontana et al., “SARS-CoV-2 Infection in Dialysis Patients in Northern Italy: A Single-Centre Experience,” [cited by applicant]
Gagliardi et al., “COVID-19 and the Kidney: From Epidemiology to Clinical Practice,” [cited by applicant]
Gallieni et al., “Delivering safe and effective hemodialysis in patients with suspected or confirmed COVID-19 infection: a single-center perspective from Italy,” [cited by applicant]
Gedney, N., “Long-Term Hemodialysis During the COVID-19 Pandemic,” [cited by applicant]
Guo et al., “Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease” [cited by applicant]
Ikizler T.A., “COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?” [cited by applicant]
Jager et al., “Results from the ERAEDTA Registry Indicate a High Mortality Due to COVID-19 in Dialysis Patients and Kidney Transplant Recipients Across Europe,” [cited by applicant]
Kikuchi et al., “COVID-19 of Dialysis Patients in Japan: Current Status and Guidance on Preventive Measures,” Ther. Apher. Dial., 24, 361-365 (2020). [cited by applicant]
Kliger et al., “Mitigating Risk of COVID-19 in Dialysis Facilities” [cited by applicant]
Leung et al., “First-wave COVID-19 Transmissibility and Severity in China Outside Hubei After Control Measures, and Second-Wave Scenario Planning: A Modelling Impact Assessment,” [cited by applicant]
Li et al., “Risk Factors for Severity and Mortality in Adult COVID-19 Inpatients in Wuhan,” [cited by applicant]
Lundberg et al., “A Unified Approach to Interpreting Model Predictions,” 31st Conference on Neural Information Processing Systems, Long Beach, CA, USA (2017). [cited by applicant]
Lundberg et al., “From Local Explanations to Global Understanding With Explainable AI for Trees,” [cited by applicant]
Ma et al., “COVID-19 in Hemodialysis (HD) Patients: Report From One HD Center in Wuhan China ,” medRxiv: 2020.2002.2024.20027201 (2020). [cited by applicant]
McCall, B., “COVID-19 and artificial intelligence: protecting health-care workers and curbing the Spread,” [cited by applicant]
Meng et al., “Development and utilization of an intelligent application for aiding COVID-19 diagnosis,” medRxiv: 2020.2003.2018.20035816 (2020). [cited by applicant]
Mokrzycki et al., “Management of hemodialysis patients with suspected or confirmed COVID-19 infection: perspective of two nephrologists in the United States,” [cited by applicant]
Monaghan et al., “Machine Learning for Prediction of Patients on Hemodialysis with an Undetected SARS-CoV-2 Infection,” [cited by applicant]
Neumann, M.E., “Latest data show 305 dialysis patient deaths due to COVID-19 in the US,” https://www.healio.com/nephrology/infectioncontrol/news/online/%7B3a263aa9-ad59-4c3f-aab7-07b8395508e5%7D/latest-data-show-305-dia… [cited by applicant]
Niiler, E., “An AI Epidemiologist Sent the First Warnings of the Wuhan Virus,” Wired, https://www.wired.com/story/ai-epidemiologist-wuhan-public-health-warnings/ (Jan. 25, 2020). [cited by applicant]
Roncon et al., “Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome,” [cited by applicant]
Saito et al., “The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets,” PLoS One, 10: e0118432 (Mar. 4, 2015). [cited by applicant]
Shaikh et al., “Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis,” [cited by applicant]
Shapley L.S., “A Value for n-Person Games,” In: H. W. Kuhn and A. W. Tucker, Eds., [cited by applicant]
Siordia J.A., Jr., “Epidemiology and clinical features of COVID-19: A review of current literature,” [cited by applicant]
Song et al., “COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients,” medRxiv: 2020.2003.2005.20031906 (2020). [cited by applicant]
Štrumbelj et al., “Explaining prediction models and individual predictions with feature Contributions,” [cited by applicant]
United States Renal Data System, “Epidemiology of kidney disease in the United States,” [cited by applicant]
Usvyat et al., “Circadian variations in body temperature during dialysis,” [cited by applicant]
Vaishya et al., “Artificial Intelligence (AI) applications for COVID-19 Pandemic,” [cited by applicant]
Wang, H., “Maintenance Hemodialysis and Coronavirus Disease 2019 (COVID-19): Saving Lives With Caution, Care, and Courage,” [cited by applicant]
Wynants et al., “Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal,” [cited by applicant]
Xiong et al., “Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China,” [cited by applicant]
Xu et al., “Beware of the second wave of COVID-19,” [cited by applicant]
Zhou et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” [cited by applicant]